Do analysts prefer ICCC or PLRZ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImmuCell 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Polyrizon 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, ICCC or PLRZ?

ImmuCell has higher revenue and earnings than Polyrizon. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ImmuCell $27.64M 3.22 -$1.04M $0.08 122.50 Polyrizon N/A N/A -$3.34M N/A N/A

Do analysts prefer NTRB or PLRZ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nutriband 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Polyrizon 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, NTRB or PLRZ?

Polyrizon has lower revenue, but higher earnings than Nutriband. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nutriband $2.04M 39.64 -$8.23M -$0.53 N/A Polyrizon N/A N/A -$3.34M N/A N/A

Is NTRB or PLRZ more profitable?

Polyrizon has a net margin of 0.00% compared to Nutriband's net margin of -430.35%. Polyrizon's return on equity of 0.00% beat Nutriband's return on equity. Company Net Margins Return on Equity Return on Assets Nutriband -430.35% -109.07% -95.54% Polyrizon N/A N/A N/A

Does the media prefer NTRB or PLRZ?

In the previous week, Polyrizon had 3 more articles in the media than Nutriband. MarketBeat recorded 6 mentions for Polyrizon and 3 mentions for Nutriband. Polyrizon's average media sentiment score of 0.58 beat Nutriband's score of 0.00 indicating that Polyrizon is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nutriband 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Polyrizon 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer CGTX or PLRZ?

Cognition Therapeutics currently has a consensus price target of $3.33, suggesting a potential upside of 280.13%. Given Cognition Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Cognition Therapeutics is more favorable than Polyrizon. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cognition Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Polyrizon 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, CGTX or PLRZ?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cognition Therapeutics N/A N/A -$23.49M -$0.17 N/A Polyrizon N/A N/A -$3.34M N/A N/A

Is CGTX or PLRZ more profitable?

Polyrizon's return on equity of 0.00% beat Cognition Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cognition Therapeutics N/A -50.17% -40.22% Polyrizon N/A N/A N/A

Does the media prefer CGTX or PLRZ?

In the previous week, Polyrizon had 4 more articles in the media than Cognition Therapeutics. MarketBeat recorded 6 mentions for Polyrizon and 2 mentions for Cognition Therapeutics. Polyrizon's average media sentiment score of 0.58 beat Cognition Therapeutics' score of 0.00 indicating that Polyrizon is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cognition Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Polyrizon 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer MNOV or PLRZ?

MediciNova currently has a consensus price target of $7.75, indicating a potential upside of 409.87%. Given MediciNova's stronger consensus rating and higher possible upside, equities research analysts plainly believe MediciNova is more favorable than Polyrizon. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MediciNova 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.71 Polyrizon 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, MNOV or PLRZ?

Polyrizon has lower revenue, but higher earnings than MediciNova. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MediciNova $920.48K 81.28 -$12M -$0.21 N/A Polyrizon N/A N/A -$3.34M N/A N/A

Does the media refer more to MNOV or PLRZ?

In the previous week, Polyrizon had 1 more articles in the media than MediciNova. MarketBeat recorded 6 mentions for Polyrizon and 5 mentions for MediciNova. Polyrizon's average media sentiment score of 0.58 beat MediciNova's score of 0.56 indicating that Polyrizon is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MediciNova 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Polyrizon 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate PLRZ or RFL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Polyrizon 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Rafael 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, PLRZ or RFL?

Polyrizon has higher earnings, but lower revenue than Rafael. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Polyrizon N/A N/A -$3.34M N/A N/A Rafael $920K 91.17 -$30.52M -$0.68 N/A

Is PLRZ or RFL more profitable?

Polyrizon has a net margin of 0.00% compared to Rafael's net margin of -3,321.74%. Polyrizon's return on equity of 0.00% beat Rafael's return on equity. Company Net Margins Return on Equity Return on Assets Polyrizon N/A N/A N/A Rafael -3,321.74% -41.27% -35.32%

Does the media favor PLRZ or RFL?

In the previous week, Polyrizon had 3 more articles in the media than Rafael. MarketBeat recorded 6 mentions for Polyrizon and 3 mentions for Rafael. Polyrizon's average media sentiment score of 0.58 beat Rafael's score of -0.37 indicating that Polyrizon is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Polyrizon 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rafael 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Polyrizon (PLRZ) Competitors

$8.99 +0.12 (+1.35%)

Closing price 10/9/2026 03:59 PM Eastern

Extended Trading

$9.28 +0.29 (+3.17%)

As of 10/9/2026 07:30 PM Eastern

Compare

PLRZ vs. ICCC, NTRB, CGTX, MNOV, and RFL

Should you buy Polyrizon stock or one of its competitors? Polyrizon's main competitors and comparable companies include ImmuCell (ICCC), Nutriband (NTRB), Cognition Therapeutics (CGTX), MediciNova (MNOV), and Rafael (RFL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Polyrizon compare to ImmuCell?

ImmuCell (NASDAQ:ICCC) and Polyrizon (NASDAQ:PLRZ) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, media sentiment, analyst recommendations and risk.

ImmuCell has a net margin of 2.57% compared to Polyrizon's net margin of 0.00%. ImmuCell's return on equity of 2.69% beat Polyrizon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmuCell	2.57%	2.69%	1.76%
Polyrizon	N/A	N/A	N/A

ImmuCell has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market. Comparatively, Polyrizon has a beta of -1.2, indicating that its stock price is 220% less volatile than the broader market.

13.5% of ImmuCell shares are owned by institutional investors. 5.7% of ImmuCell shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmuCell	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

ImmuCell has higher revenue and earnings than Polyrizon.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmuCell	$27.64M	3.22	-$1.04M	$0.08	122.50
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A

In the previous week, Polyrizon had 5 more articles in the media than ImmuCell. MarketBeat recorded 6 mentions for Polyrizon and 1 mentions for ImmuCell. Polyrizon's average media sentiment score of 0.58 beat ImmuCell's score of 0.00 indicating that Polyrizon is being referred to more favorably in the news media.

Company	Overall Sentiment
ImmuCell	Neutral
Polyrizon	Positive

Summary

ImmuCell beats Polyrizon on 9 of the 11 factors compared between the two stocks.

How does Polyrizon compare to Nutriband?

Nutriband (NASDAQ:NTRB) and Polyrizon (NASDAQ:PLRZ) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Polyrizon has a net margin of 0.00% compared to Nutriband's net margin of -430.35%. Polyrizon's return on equity of 0.00% beat Nutriband's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nutriband	-430.35%	-109.07%	-95.54%
Polyrizon	N/A	N/A	N/A

19.7% of Nutriband shares are owned by institutional investors. 52.2% of Nutriband shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Nutriband has a beta of 1.92, indicating that its stock price is 92% more volatile than the broader market. Comparatively, Polyrizon has a beta of -1.2, indicating that its stock price is 220% less volatile than the broader market.

Polyrizon has lower revenue, but higher earnings than Nutriband.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nutriband	$2.04M	39.64	-$8.23M	-$0.53	N/A
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A

In the previous week, Polyrizon had 3 more articles in the media than Nutriband. MarketBeat recorded 6 mentions for Polyrizon and 3 mentions for Nutriband. Polyrizon's average media sentiment score of 0.58 beat Nutriband's score of 0.00 indicating that Polyrizon is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nutriband	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Polyrizon	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nutriband	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Polyrizon beats Nutriband on 6 of the 11 factors compared between the two stocks.

How does Polyrizon compare to Cognition Therapeutics?

Cognition Therapeutics (NASDAQ:CGTX) and Polyrizon (NASDAQ:PLRZ) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, media sentiment, valuation, risk and analyst recommendations.

43.3% of Cognition Therapeutics shares are held by institutional investors. 11.1% of Cognition Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Polyrizon's return on equity of 0.00% beat Cognition Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cognition Therapeutics	N/A	-50.17%	-40.22%
Polyrizon	N/A	N/A	N/A

Cognition Therapeutics has a beta of 1.8, indicating that its share price is 80% more volatile than the broader market. Comparatively, Polyrizon has a beta of -1.2, indicating that its share price is 220% less volatile than the broader market.

Cognition Therapeutics currently has a consensus price target of $3.33, suggesting a potential upside of 280.13%. Given Cognition Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Cognition Therapeutics is more favorable than Polyrizon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Polyrizon had 4 more articles in the media than Cognition Therapeutics. MarketBeat recorded 6 mentions for Polyrizon and 2 mentions for Cognition Therapeutics. Polyrizon's average media sentiment score of 0.58 beat Cognition Therapeutics' score of 0.00 indicating that Polyrizon is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cognition Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Polyrizon	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.17	N/A
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A

Summary

Cognition Therapeutics beats Polyrizon on 6 of the 11 factors compared between the two stocks.

How does Polyrizon compare to MediciNova?

MediciNova (NASDAQ:MNOV) and Polyrizon (NASDAQ:PLRZ) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, media sentiment, valuation, earnings, institutional ownership, analyst recommendations and dividends.

Polyrizon has lower revenue, but higher earnings than MediciNova.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediciNova	$920.48K	81.28	-$12M	-$0.21	N/A
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A

MediciNova has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market. Comparatively, Polyrizon has a beta of -1.2, meaning that its stock price is 220% less volatile than the broader market.

Polyrizon has a net margin of 0.00% compared to MediciNova's net margin of -1,168.70%. Polyrizon's return on equity of 0.00% beat MediciNova's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MediciNova	-1,168.70%	-26.51%	-24.39%
Polyrizon	N/A	N/A	N/A

MediciNova currently has a consensus price target of $7.75, indicating a potential upside of 409.87%. Given MediciNova's stronger consensus rating and higher possible upside, equities research analysts plainly believe MediciNova is more favorable than Polyrizon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediciNova	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Polyrizon had 1 more articles in the media than MediciNova. MarketBeat recorded 6 mentions for Polyrizon and 5 mentions for MediciNova. Polyrizon's average media sentiment score of 0.58 beat MediciNova's score of 0.56 indicating that Polyrizon is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MediciNova	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Polyrizon	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

9.9% of MediciNova shares are held by institutional investors. 14.0% of MediciNova shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

MediciNova beats Polyrizon on 8 of the 14 factors compared between the two stocks.

How does Polyrizon compare to Rafael?

Polyrizon (NASDAQ:PLRZ) and Rafael (NYSE:RFL) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.

Polyrizon has a beta of -1.2, indicating that its stock price is 220% less volatile than the broader market. Comparatively, Rafael has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market.

Polyrizon has a net margin of 0.00% compared to Rafael's net margin of -3,321.74%. Polyrizon's return on equity of 0.00% beat Rafael's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Polyrizon	N/A	N/A	N/A
Rafael	-3,321.74%	-41.27%	-35.32%

Polyrizon has higher earnings, but lower revenue than Rafael.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A
Rafael	$920K	91.17	-$30.52M	-$0.68	N/A

In the previous week, Polyrizon had 3 more articles in the media than Rafael. MarketBeat recorded 6 mentions for Polyrizon and 3 mentions for Rafael. Polyrizon's average media sentiment score of 0.58 beat Rafael's score of -0.37 indicating that Polyrizon is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Polyrizon	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rafael	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

11.3% of Rafael shares are owned by institutional investors. 32.9% of Rafael shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Rafael	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Polyrizon beats Rafael on 6 of the 10 factors compared between the two stocks.

Get Polyrizon News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLRZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PLRZ vs. The Competition

Export

Metric	Polyrizon	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$21.54M	$12.35B	$7.16B	$13.21B
Dividend Yield	N/A	2.64%	2.53%	16.37%
P/E Ratio	N/A	797.58	274.15	26.16
Price / Sales	N/A	939.82	635.98	112.53
Price / Cash	N/A	85.97	76.38	53.09
Price / Book	0.69	10.71	11.21	6.34
Net Income	-$3.34M	$2.84B	$3.50B	$381.90M
7 Day Performance	-6.45%	-0.93%	-0.90%	-1.41%
1 Month Performance	-19.95%	-4.91%	-4.44%	-3.48%
1 Year Performance	33.78%	-4.13%	6.96%	1.16%

Polyrizon Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PLRZ Polyrizon	1.3362 of 5 stars	$8.99 +1.4%	N/A	+19.9%	$21.54M	N/A	N/A	1	Analyst Downgrade Gap Down
ICCC ImmuCell	0.5191 of 5 stars	$9.75 +1.6%	N/A	+45.8%	$88.53M	$27.64M	121.89	73	Gap Up
NTRB Nutriband	0.8996 of 5 stars	$7.28 -1.1%	N/A	-15.9%	$88.53M	$2.04M	N/A	3	News Coverage
CGTX Cognition Therapeutics	1.762 of 5 stars	$0.93 +3.8%	$3.33 +260.3%	-55.0%	$87.97M	N/A	N/A	14	News Coverage
MNOV MediciNova	3.8004 of 5 stars	$1.78 +9.2%	$7.75 +335.4%	+24.1%	$87.61M	$410K	N/A	6	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PLRZ) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Polyrizon (PLRZ) Competitors